Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kiyoshi Yoshimura

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Cancer Genomics & Proteomics|December 27, 2024
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint InhibitorsTomoyuki Ishiguro, Kazuyuki Takeda, Daisuke Takayanagi, et al.
Medicine|January 14, 2022
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case reportKazuyuki Hamada, Kiyoshi Yoshimura, Kazuhiko Oshinomi, et al.
Biomedicines|December 24, 2021
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 AntibodiesRyotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, et al.
Frontiers in Immunology|December 29, 2025
Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire studyHirotsugu Ariizumi, Miyuki Shimazui, Chisato Ogawa, et al.
Frontiers in Oncology|October 28, 2024
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patientsYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
Anticancer Research|July 26, 2024
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to TreatmentYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
International Journal of Radiation Oncology, Biology, Physics|September 26, 2013
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer modelSatoshi Wada, Timothy J Harris, Erik Tryggestad, et al.
Cancers|July 29, 2025
Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot StudyMakoto Watanabe, Katsuaki Ieguchi, Takashi Shimizu, et al.
Biomedicines|December 30, 2025
Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective StudyRisako Suzuki, Ryotaro Ohkuma, Makoto Watanabe, et al.
Frontiers in Oncology|July 29, 2025
Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancersMakoto Watanabe, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Cancer Genomics & Proteomics|December 27, 2024
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint InhibitorsTomoyuki Ishiguro, Kazuyuki Takeda, Daisuke Takayanagi, et al.
Medicine|January 14, 2022
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case reportKazuyuki Hamada, Kiyoshi Yoshimura, Kazuhiko Oshinomi, et al.
Biomedicines|December 24, 2021
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 AntibodiesRyotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, et al.
Frontiers in Immunology|December 29, 2025
Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire studyHirotsugu Ariizumi, Miyuki Shimazui, Chisato Ogawa, et al.
Frontiers in Oncology|October 28, 2024
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patientsYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
Anticancer Research|July 26, 2024
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to TreatmentYuya Hirasawa, Yutaro Kubota, Emiko Mura, et al.
International Journal of Radiation Oncology, Biology, Physics|September 26, 2013
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer modelSatoshi Wada, Timothy J Harris, Erik Tryggestad, et al.
Cancers|July 29, 2025
Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot StudyMakoto Watanabe, Katsuaki Ieguchi, Takashi Shimizu, et al.
Biomedicines|December 30, 2025
Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective StudyRisako Suzuki, Ryotaro Ohkuma, Makoto Watanabe, et al.
Frontiers in Oncology|July 29, 2025
Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancersMakoto Watanabe, Katsuaki Ieguchi, Nobuyuki Onishi, et al.
Pageof 11